Polymorphic repeat in AIB1 does not alter breast cancer risk
暂无分享,去创建一个
W. Willett | F. Speizer | G. Colditz | D. Spiegelman | D. Hunter | Myles A Brown | C. Haiman | S. Hankinson | Myles A. Brown
[1] G. Giles,et al. Androgen receptor exon 1 CAG repeat length and breast cancer in women before age forty years. , 1999, Journal of the National Cancer Institute.
[2] W. Willett,et al. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. , 1999, Cancer research.
[3] K. Buetow,et al. Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk , 1999, British Journal of Cancer.
[4] P. Meltzer,et al. In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[5] J. Manson,et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. , 1998, Journal of the National Cancer Institute.
[6] A. Berchuck,et al. Progesterone receptor gene polymorphism and risk for breast and ovarian cancer. , 1998, British Journal of Cancer.
[7] G. Coetzee,et al. Polymorphic exonic CAG microsatellites in the gene amplified in breast cancer (AIB1 gene) , 1998, Clinical genetics.
[8] G. Colditz,et al. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. , 1998, Journal of the National Cancer Institute.
[9] G. Giles,et al. Estrogen receptor polymorphism at codon 325 and risk of breast cancer in women before age forty. , 1998, Journal of the National Cancer Institute.
[10] A. Børresen-Dale,et al. A rare CYP19 (aromatase) variant may increase the risk of breast cancer. , 1998, Pharmacogenetics.
[11] P. Meltzer,et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. , 1997, Science.
[12] P. Kantoff,et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[13] G. Coetzee,et al. A polymorphism in the CYP17 gene increases the risk of breast cancer. , 1997, Cancer research.
[14] J. Manson,et al. Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. , 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[15] N. Chamberlain,et al. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. , 1994, Nucleic acids research.
[16] P. Kantoff,et al. Amplified in breast cancer-1 glutamine repeat and prostate cancer risk , 2000 .
[17] H. Li,et al. Coactivation and corepression in transcriptional regulation by steroid/nuclear hormone receptors. , 1998, Critical reviews in eukaryotic gene expression.
[18] G. Secreto,et al. ENDOGENOUS HORMONES AND BREAST CANCER , 1998 .
[19] S L Zeger,et al. Regression analysis for correlated data. , 1993, Annual review of public health.
[20] L. Bernstein,et al. Endogenous hormones and breast cancer risk. , 1993, Epidemiologic reviews.